4-Benzyl-1-[4-(4-fluorophenyl)-4-oxo-1-butyl]piperidine | 35623-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Benzyl-1-[4-(4-fluorophenyl)-4-oxo-1-butyl]piperidine
• 英文别名: 4'-Fluor-4-(4-benzylpiperidin)-butyrophenon；4-(4-Benzyl-piperidin-1-yl)-1-(4-fluoro-phenyl)-butan-1-one；4-(4-benzylpiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one
• CAS: 35623-04-2
• 化学式: C₂₂H₂₆FNO
• 分子量: 339.453
• InChiKey: IZNJLJHYICMJAT-UHFFFAOYSA-N

物化性质

• 沸点：
  475.0±25.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-苄基哌啶 、 4-氯-4'-氟苯丁酮 在 potassium carbonate 、 sodium iodide 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以6%的产率得到4-Benzyl-1-[4-(4-fluorophenyl)-4-oxo-1-butyl]piperidine
  参考文献：
  名称：

  Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist

  摘要：

  DOM [i.e., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane] is a 5-HT1C/2 serotonin agonist that exerts stimulus control of behavior in animals. In order to determine if the discriminative stimulus effect of DOM is 5-HT1C- or 5-HT2-mediated, it would be informative to conduct tests of stimulus antagonism with a 5-HT1C- or 5-HT2-selective antagonist. To date, no such agents exist. Although the neuroleptic agent spiperone binds at D2 dopamine receptors and 5-HT1A serotonin receptors, (a) it displays about a 1000-fold selectivity for 5-HT2 versus 5-HT1C sites and (b) it has been used as a ''5-HT2-selective'' antagonist. Because spiperone is a behaviorally disruptive agent, it is not suitable for use in drug-discrimination studies. Using the spiperone molecule as a starting point, a limited structure-affinity investigation was conducted in order to identify a suitable antagonist with high affinity and selectivity for 5-HT2 receptors, and yet an antagonist that might lack the disruptive actions of spiperone. Various modifications of the spiperone molecule were examined, but most resulted in decreased 5-HT2 affinity or in loss of selectivity. One compound, 8-[3-(4-fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one(26), was shown to bind at 5-HT2 sites with high affinity (K(i) = 2 nM) and >2,000-fold selectivity versus 5-HT1C sites. In tests of stimulus antagonism using rats trained to discriminate 1 mg/kg of DOM from saline vehicle, 26 behaved as a potent antagonist (ED50 = 0.003 mg/kg) and lacked the disruptive effects associated with spiperone. As such, (a) it would appear that the DOM stimulus is primarily a 5-HT2-mediated, and not 5-HT1C-mediated, phenomenon, and (b) compound 26 may find application in other pharmacologic investigations where spiperone may not be a suitable antagonist.

  DOI：

  10.1021/jm00069a010

文献信息

• Compounds with activity on muscarinic receptors
  申请人：——

  公开号：US20030144285A1

  公开（公告）日：2003-07-31

  Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.

  本发明提供了化合物和方法，用于减轻或治疗通过改变毒蕈碱受体m1的活性具有益处的疾病或病症。在该方法中，向需要此类治疗的患者施用选择性毒蕈碱受体m1激动剂化合物的治疗有效量。
• COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS
  申请人：Brann Mark

  公开号：US20080108618A1

  公开（公告）日：2008-05-08

  Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.

  提供了化合物和方法，用于缓解或治疗改变毒蕈碱受体m1活性有益影响的疾病或状况。在该方法中，向需要此类治疗的患者施用选择性毒蕈碱受体m1激动剂化合物的治疗有效量。
• AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS
  申请人：Yamaguchi Isamu

  公开号：US20090075974A1

  公开（公告）日：2009-03-19

  Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a 5-HT2C receptor. Preferably the binding activity (pKi) of the 5-HT2A receptor antagonist to the 5-HT2A receptor is at least 7.0, and more preferably at least 8.0. The present invention also provides a method of identifying a candidate substance for prophylactic and therapeutic agent for pancreatitis, comprising determining whether a test substance has a 5-HT2A receptor antagonistic activity.
• US6528529B1
  申请人：——

  公开号：US6528529B1

  公开（公告）日：2003-03-04
• US7485651B2
  申请人：——

  公开号：US7485651B2

  公开（公告）日：2009-02-03